#Cumulus_Neuroscience
LightNews LightNews
newsen.bsky.social
Cumulus Neuroscience's NeuLogiq Platform Validates Safety for Zalsupindole in Treating Major Depressive Disorder#United_States#Miami#Cumulus_Neuroscience#NeuLogiq_Platform#zalsupindole
Cumulus Neuroscience's NeuLogiq Platform Validates Safety for Zalsupindole in Treating Major Depressive Disorder
Cumulus Neuroscience showcased their NeuLogiq Platform at the ASCP 2026 Conference, confirming no cognitive impairment from the neuroplastogen zalsupindole in a Phase 1b trial.
third-news.com
May 28, 2026 at 4:03 PM
newsen.bsky.social
Cumulus Neuroscience Expands its Vision into the Japanese Market Through Collaboration with Shionogi & Co., Ltd.#Japan#Osaka#Cumulus_Neuroscience#Shionogi#NeuLogiq_Platform
Cumulus Neuroscience Expands its Vision into the Japanese Market Through Collaboration with Shionogi & Co., Ltd.
Cumulus Neuroscience enters the Japanese market through a partnership with Shionogi, aiming to enhance cognitive biomarker research for innovative therapies.
third-news.com
February 10, 2026 at 1:34 PM
newsen.bsky.social
Cumulus Neuroscience Unveils Groundbreaking CNS Data at ISCTM 2026 Autumn Conference#Cumulus_Neuroscience#NeuLogiq_Platform#CNS_Trials
Cumulus Neuroscience Unveils Groundbreaking CNS Data at ISCTM 2026 Autumn Conference
Cumulus Neuroscience shared innovative findings at ISCTM 2026, showcasing high adherence and usability in CNS clinical trials, enhancing approaches for BPD and Alzheimer's.
third-news.com
September 16, 2026 at 10:05 PM
newsen.bsky.social
Cumulus Neuroscience's NeuLogiq® Platform Shows Promise for At-Home Cognitive Assessment in ALS and FTD Patients#Ireland#ALS#Belfast#Cumulus_Neuroscience#NeuLogiq
Cumulus Neuroscience's NeuLogiq® Platform Shows Promise for At-Home Cognitive Assessment in ALS and FTD Patients
Cumulus Neuroscience reveals compelling results from CNS-102, indicating that NeuLogiq® can effectively assess cognitive function at home for ALS and FTD patients.
third-news.com
August 20, 2026 at 6:27 AM
newsen.bsky.social
Cumulus Neuroscience's NeuLogiq® Platform Advances At-Home Cognitive Assessments for ALS and FTD Patients#USA#Belfast#Cumulus_Neuroscience#NeuLogiq®#ALS-FTD
Cumulus Neuroscience's NeuLogiq® Platform Advances At-Home Cognitive Assessments for ALS and FTD Patients
Cumulus Neuroscience's NeuLogiq® Platform shows promise for at-home cognitive assessments in ALS and FTD patients, improving clinical trials.
third-news.com
August 18, 2026 at 4:09 PM
newsen.bsky.social
Cumulus Neuroscience's NeuLogiq Platform Revolutionizes At-Home Cognitive Assessment for ALS and FTD Patients#United_Kingdom#ALS#Belfast#Cumulus_Neuroscience#NeuLogiq
Cumulus Neuroscience's NeuLogiq Platform Revolutionizes At-Home Cognitive Assessment for ALS and FTD Patients
Cumulus Neuroscience's groundbreaking NeuLogiq Platform has been validated for at-home cognitive assessment in ALS and FTD, offering new hope and ease of use for patients.
third-news.com
August 18, 2026 at 3:47 PM
newsen.bsky.social
Cumulus Neuroscience Unveils Breakthrough Findings at AAIC 2026 on Digital Assessment for Alzheimer’s Trials#USA#London#Cumulus_Neuroscience#Alzheimer_Study#NeuroLogiq_Platform
Cumulus Neuroscience Unveils Breakthrough Findings at AAIC 2026 on Digital Assessment for Alzheimer’s Trials
Discover how Cumulus Neuroscience's novel two-minute digital task challenges traditional Alzheimer's screening methods, offering new hope for early detection and participant recruitment.
third-news.com
July 16, 2026 at 7:30 AM
newsen.bsky.social
Cumulus Neuroscience Unveils Groundbreaking Data on Alzheimer’s Trial Screening at AAIC 2026#USA#London#Cumulus_Neuroscience#NeuLogiq#Alzheimer's_Research
Cumulus Neuroscience Unveils Groundbreaking Data on Alzheimer’s Trial Screening at AAIC 2026
Cumulus Neuroscience showcased compelling data at AAIC 2026, revealing a two-minute digital task that meets clinical benchmarks for Alzheimer's trial participant selection.
third-news.com
July 15, 2026 at 2:33 PM
newsen.bsky.social
Cumulus Neuroscience's Innovative Digital Task Enhances Alzheimer's Trial Efficiency#USA#London#Cumulus_Neuroscience#NeuLogiq#Alzheimer's_Trials
Cumulus Neuroscience's Innovative Digital Task Enhances Alzheimer's Trial Efficiency
Cumulus Neuroscience unveils groundbreaking data demonstrating that its two-minute digital task surpasses clinical benchmarks in Alzheimer's trials, enhancing recruitment efficiency.
third-news.com
July 15, 2026 at 9:30 AM
newsen.bsky.social
Cumulus Neuroscience Shows Promising Results for Alzheimer's Trials with Innovative Digital Tool#London#United_Kingdom#Alzheimer's_Disease#Cumulus_Neuroscience#NeuLogiq_Platform
Cumulus Neuroscience Shows Promising Results for Alzheimer's Trials with Innovative Digital Tool
Cumulus Neuroscience has unveiled data at AAIC 2026 highlighting its new digital cognitive task that competes with standard clinical assessments. This innovation aims to improve Alzheimer's trial efficiency.
third-news.com
July 15, 2026 at 9:08 AM
newsen.bsky.social
Cumulus Neuroscience and Muse Innovate Sleep EEG Technology for Clinical Trials#London#United_Kingdom#Cumulus_Neuroscience#NeuLogiq#Muse_by_Interaxon
Cumulus Neuroscience and Muse Innovate Sleep EEG Technology for Clinical Trials
Cumulus Neuroscience and Muse by Interaxon have announced a collaboration to integrate sleep EEG technology for clinical trials. This marks a significant advancement in neuroscience research.
third-news.com
July 6, 2026 at 12:14 PM
newsen.bsky.social
Cumulus Neuroscience Unveils Promising NeuLogiq® Platform for Alzheimer's Assessment at Home#United_Kingdom#Alzheimer's_Disease#Belfast#Cumulus_Neuroscience#NeuLogiq
Cumulus Neuroscience Unveils Promising NeuLogiq® Platform for Alzheimer's Assessment at Home
Discover how the NeuLogiq® Platform is paving the way for at-home cognitive assessments in Alzheimer's patients, showcasing high usability and adherence.
third-news.com
June 30, 2026 at 1:33 PM
newsen.bsky.social
Cumulus Neuroscience Welcomes Dr. Ricardo Sáinz Fuertes as New Board Chair#United_Kingdom#digital_health#Belfast#Cumulus_Neuroscience#NeuLogiq_Platform
Cumulus Neuroscience Welcomes Dr. Ricardo Sáinz Fuertes as New Board Chair
Cumulus Neuroscience has appointed Dr. Ricardo Sáinz Fuertes as the new Chair of the Board, succeeding Dr. Ruth McKernan. His expertise aims to lead the company into the next phase of growth.
third-news.com
January 8, 2026 at 4:01 PM
newsen.bsky.social
Cumulus Neuroscience Confirms Neuroplasticity Measurement Using Innovative EEG Technology#United_Kingdom#EEG_Technology#Belfast#Cumulus_Neuroscience#Neuroplasticity
Cumulus Neuroscience Confirms Neuroplasticity Measurement Using Innovative EEG Technology
Cumulus Neuroscience has published a new study validating a low-burden method for assessing neuroplasticity, revolutionizing clinical trials.
third-news.com
January 6, 2026 at 10:06 AM
newsen.bsky.social
Revolutionizing Alzheimer’s Trials: Cumulus Neuroscience's Insights from CTAD 2025#United_States#San_Diego#Alzheimer's_Disease#Cumulus_Neuroscience#NeuLogiq
Revolutionizing Alzheimer’s Trials: Cumulus Neuroscience's Insights from CTAD 2025
Cumulus Neuroscience unveiled pivotal findings at CTAD 2025, showcasing how at-home digital endpoints enhance trial efficiency and cost-effectiveness in Alzheimer's research.
third-news.com
December 4, 2025 at 3:18 PM
newsen.bsky.social
Cumulus Neuroscience Showcases Innovative Data at Major Neuroscience Conferences#United_Kingdom#Clinical_Trials#Amsterdam#Cumulus_Neuroscience#NeuLogiq
Cumulus Neuroscience Showcases Innovative Data at Major Neuroscience Conferences
Cumulus Neuroscience has presented groundbreaking findings at prominent neuroscience events, highlighting advancements in clinical trials and digital health technology.
third-news.com
October 13, 2025 at 8:05 AM
newsen.bsky.social
Cumulus Neuroscience Welcomes Robert Ballantine to Board of Directors#United_Kingdom#Belfast#Cumulus_Neuroscience#NeuLogiq#Robert_Ballantine
Cumulus Neuroscience Welcomes Robert Ballantine to Board of Directors
Cumulus Neuroscience, a leader in digital health, announces Robert Ballantine's appointment to its board, enhancing its commitment to neuroscience innovations.
third-news.com
September 10, 2025 at 8:04 AM
newsen.bsky.social
Revolutionizing Alzheimer's Diagnosis with a 3-Minute EEG Test#United_Kingdom#Alzheimer's#Belfast#Cumulus_Neuroscience#Fastball_EEG
Revolutionizing Alzheimer's Diagnosis with a 3-Minute EEG Test
Cumulus Neuroscience has developed a pioneering 3-minute EEG test that can detect memory impairment, offering potential for earlier Alzheimer's diagnosis and improved patient care.
third-news.com
September 2, 2025 at 9:09 PM
newsen.bsky.social
Cumulus Neuroscience Showcases Breakthrough Findings on Alzheimer's at AAIC 2025 Annual Meeting#Canada#Toronto#Alzheimer's#Cumulus_Neuroscience#CNS-101
Cumulus Neuroscience Showcases Breakthrough Findings on Alzheimer's at AAIC 2025 Annual Meeting
At the AAIC 2025 Annual Meeting, Cumulus Neuroscience presented insights from the CNS-101 study, highlighting the effectiveness of at-home cognitive assessments for Alzheimer's patients.
third-news.com
July 28, 2025 at 12:06 PM
newsen.bsky.social
NeuLogiq® Platform Validates Electrophysiological Markers for Major Depression in Clinical Trials#United_States#Scottsdale,_Arizona#Cumulus_Neuroscience#Major_Depressive_Disorder#NeuLogiq_Platform
NeuLogiq® Platform Validates Electrophysiological Markers for Major Depression in Clinical Trials
Cumulus Neuroscience presents groundbreaking findings demonstrating the NeuLogiq® Platform's ability to identify key electrophysiological signals in patients with Major Depressive Disorder, enhancing clinical trials.
third-news.com
May 29, 2025 at 12:08 PM
newsen.bsky.social
Cumulus Neuroscience Unveils Groundbreaking Findings at AD/PD 2025 Annual Meeting#None#Vienna#Alzheimer's_Disease#Cumulus_Neuroscience#NeuLogiq
Cumulus Neuroscience Unveils Groundbreaking Findings at AD/PD 2025 Annual Meeting
Cumulus Neuroscience presented pivotal data at the AD/PD 2025 Annual Meeting, validating its NeuLogiq® Platform for Alzheimer's and ALS-FTD assessments.
third-news.com
April 4, 2025 at 12:15 PM